Contrast MRI can predict glioblastoma outcomes

By staff writers
December 4, 2012

Changes in tumor enhancement on postgadolinium T1-weighted MRI scans are highly predictive of which patients with recurrent glioblastoma will benefit from second-line therapy that includes the antiangiogenic drug bevacizumab, according to a study presented last week at the RSNA 2012 conference.

Determining whether a patient's tumor is responding to a therapeutic regimen with bevacizumab has presented challenges in MRI interpretation due to the drug's potential for decreasing tumor enhancement independent of decreasing tumor burden.

The findings were presented by Dr. Jerrold Boxerman, PhD, assistant professor at the Warren Alpert Medical School of Brown University, vice chair for brain cancer research of the American College of Radiology Imaging Network (ACRIN) head/neck/neuro committee, and principal investigator for the ACRIN 6677 trial.

In a review of 123 cases, two radiologists measured 2D and 3D enhancement on postgadolinium T1-weighted MR images and 3D fluid-attenuated inversion-recovery (FLAIR) hyperintensity images. A third neuroradiologist reviewed any interpretation discrepancies.

The median overall survival of patients whose tumors had progressed after two cycles and four cycles of treatment (at eight and 16 weeks, respectively) was significantly less than that of patients whose tumors did not progress on the 2D T1 images and 3D T1 images, but not on the FLAIR images.

"Our study results demonstrate that even though tumor enhancement may diminish with the use of bevacizumab, a finding of progressive enhancement on the T1-weighted images highly correlates with worse patient outcome," Boxerman said in a statement about the study. "Knowing that a patient is not benefiting from a treatment could permit a timely switch to a clinical trial evaluating an alternate therapeutic strategy."

Fasting enhances response of glioma to radiation therapy
Controlled fasting improves the effectiveness of chemotherapy and radiation therapy in mice with aggressive brain tumors, extending their survival, according...
RTOG announces glioblastoma trial results
A trial comparing two chemotherapy doses combined with radiotherapy showed equivocal results for glioblastoma. However, it did prove the feasibility of...
Stem cell irradiation helps in glioblastoma
Brain cancer patients with glioblastoma may survive longer if they undergo radiation treatments that include stem cell niches as well as their primary...
Final results reported for glioblastoma clinical trial
A final analysis of a large clinical trial spanning two continents confirms that a combination of postoperative radiation therapy and chemotherapy rather...

Copyright © 2012

Last Updated np 12/3/2012 5:42:57 PM